

## **DETAILED ACTION**

### **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Thomas Blankinship & Alex Liu on June 6, 2011.

The application has been amended as follows:

In the claims, amend claim 12 as follows:

12. A method of treating a bacterial disease of the lungs in a human or animal comprising the step of locally administering an antibacterially effective amount of:  
a mixture of ciprofloxacin embonate and ciprofloxacin hemiembonate, or  
a mixture of enrofloxacin embonate and enrofloxacin hemiembonate,  
in a powder form or powder-containing suspension.

### **REASONS FOR ALLOWANCE**

The amendments filed May 26, 2011 have been entered and fully considered. With the examiner's amendments as set forth above, the claims are in condition for allowance. The following is an examiner's statement of reasons for allowance: Claims as amended are drawn to the employment of particular salts of ciprofloxacin or enrofloxacin locally for treating bacterial

Art Unit: 1627

infection in lung. The prior art as a whole does not teach or fairly suggest the employment of the particular salts herein, which provide high efficacy.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee.

Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHENGJUN WANG whose telephone number is (571)272-0632. The examiner can normally be reached on M-F (8:30-5:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Shengjun Wang/  
Primary Examiner, Art Unit 1627

Application/Control Number: 10/775,888

Page 4

Art Unit: 1627

\*\*\*